ClinicaliQ Trial Snapshot
- Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer — Active Not Recruiting • Phase III • Oncology • NCT05425940.
- New drug combination XL092 plus atezolizumab compared to regorafenib for advanced bowel cancer that hasn't responded to standard treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy. Conditions: Colorectal Cancer Interventions: XL092, Atezolizumab, Regorafenib Lead Sponsor: Exelixis Planned Enrollment: 901 participants